Abstract
Our research offers a novel insight into the impact of smoking on the susceptibility to coronary heart disease (CHD) and myocardial infarction (MI) through the lens of epigenetic DNA methylation. By employing Mendelian Randomization, we demonstrate that smoking initiation is a causal driver of cardiovascular disease, likely mediated by specific epigenetic modifications.
Introduction
While the link between tobacco use and cardiovascular diseases like coronary heart disease (CHD) and myocardial infarction (MI) is well-established, the precise molecular mechanisms have long remained a "black box." Observational studies frequently struggle with confounding factors and reverse causation. This study addresses these challenges by investigating whether smoking-related epigenetic changes—specifically DNA methylation—are truly on the causal pathway to heart disease.
Methodology
The researchers utilized a multi-step genomic approach to establish causality and identify molecular mediators.
The study integrated several massive international datasets, including GWAS data from over 1.2 million individuals for smoking behaviors, blood DNA methylation data from the CHARGE Consortium and GoDMC database, and disease outcome data from the UK Biobank, FinnGen, and Biobank Japan. The core methodology involved:
- Two-Sample Mendelian Randomization (MR): Using genetic variants as instrumental variables to establish a clear causal direction from smoking to methylation, and methylation to disease.
- Genetic Colocalization (COLOC): Verifying that the same underlying genetic variant drives both the methylation change and the disease risk.
- Meta-Analysis: Replicating findings across diverse populations (European and Asian) to ensure robustness.
Key Results and Insights
The study revealed that "smoking initiation" (the act of starting to smoke regularly) has a more consistent causal link to CHD and MI than the quantity of cigarettes smoked per day. This suggests a biological "switch" is flipped upon initiation that significantly alters cardiovascular risk profiles.
Genetically predicted smoking initiation was associated with a significantly increased risk of CHD (OR 1.236, p=8.85E-06) and MI (OR 1.381, p=2.77E-14). The analysis identified several high-priority molecular targets:
- CHD Mediators: Robust colocalization was found for CpG sites near genes FBLN7 (extracellular matrix stability), ARHGEF12 (blood pressure regulation), and MCF2L.
- MI Mediators: Strong evidence linked heart attack risk to sites near DIABLO, FES, and CNN3.
Interestingly, the model showed an increased risk of MI associated with smoking cessation (OR 1.195). This likely reflects the "sick quitter" effect or the persistence of biological damage from long-term smoking that remains for decades after quitting.
Discussion and Limitations
The findings were validated across both European and Asian cohorts, suggesting universal biological pathways for smoking's epigenetic impact. However, some limitations remain. The methylation data was derived from peripheral blood, which may not perfectly mirror the state of heart tissue. Additionally, the study focused on individual CpG sites rather than broader "CpG islands," and lacks longitudinal data to track real-time epigenetic changes during smoking transitions.
Future research should focus on validating these blood-based markers using myocardial tissue-derived data to further refine our understanding of these epigenetic bridges.
Summary updated